teva pharmaceuticals
-
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of…
-
The Teva Turnaround: Steering a Company Comeback
CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker…
-
Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinics.…
-
Teva Announces Appointment of Richard Francis as President and CEO
Kåre Schultz to Retire After a Transformative Five-Year Tenure Setting the Stage for an Exciting Future
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
